Physician profile
Joseph Wang
NPI 1437118718
$5,906.25
in general payments reported to CMS, 2019-2025
32 companies · $632 in 2025
The $632 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,954 · 2020: $207 · 2021: $632 · 2022: $814 · 2023: $929 · 2024: $739 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Echosens North America, INC. | $987.32 | 2019 | |
| Abbvie INC. | $853.44 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $832.25 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $713.99 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $540.78 | 2019-2025 | Stelara, Tremfya |
| Phathom Pharmaceuticals, INC. | $254.54 | 2024-2025 | Voquezna |
| Allergan, INC. | $164.29 | 2019 | |
| Intercept Pharmaceuticals, INC. | $159.19 | 2021-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $135.81 | 2019-2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $116.64 | 2021-2023 | |
| Ardelyx, INC. | $107.62 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $101.59 | 2019-2025 | |
| Daiichi Sankyo INC. | $94.33 | 2019-2020 | |
| Celgene Corporation | $87.74 | 2021-2024 | Zeposia |
| Ucb, INC. | $78.89 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $73.89 | 2020-2024 | |
| Boston Scientific Corporation | $71.13 | 2019-2020 | |
| Pfizer INC. | $70.93 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $67.60 | 2024-2025 | Vowst |
| Genzyme Corporation | $62.05 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $51.69 | 2022-2023 | Rebyota |
| Pacira Pharmaceuticals Incorporated | $38.17 | 2024-2025 | Exparel, Zilretta, Iovera |
| Amgen INC. | $33.50 | 2020-2021 | |
| Celltrion USA INC. | $33.10 | 2024-2025 | Vegzelma |
| Qol Medical, LLC | $30.18 | 2022-2024 | Sucraid |
| Organon LLC | $29.94 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $25.77 | 2024 | Dupixent |
| Medtronic, INC. | $21.24 | 2024 | Interstim |
| Ethicon US, LLC | $20.56 | 2023 | Linx Reflux Management System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.27 | 2022 | |
| Elite Orthopedics, LLC | $14.52 | 2023 | |
| Capsovision, INC. | $14.29 | 2025 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.